11. Incidence of epstein-barr virus and human papiloma virus in nasopharyngeal cancer and initial treatment result
Main Article Content
Abstract
This study was conducted to estimate the incidence of Epstein-Barr Virus (EBV) and Human Papiloma Virus (HPV) in Nasopharyngeal cancer (NPC) and evaluate initial treatment result. Between October 2019 and April 2024, there were 30 NPC patients treated with radiotherapy and chemotherapy at the ENT National hospital and the tissue samples were tested to determine EBV and HPV. The average age of the 30 patients was 52.03 ± 12.36 years old. Male/female ratio = 3.2. Smoking history was 46.7%. Stage T1 (20%), T2 (30%), T3 (13.7%), T4 (36.3%). Stage N0 (26.7%), N1 (26.7%), N2 (43.3%), N3 (3.3%). The rate of EBV infection was 63.3%, the rate of HPV infection was 16.7%. The overall 3-year survival rate was 73.3%. The 3-year disease-free survival rate was 69.7%. The EBV-/HPV+ group had a higher overall and disease-free survival rate than the three groups EBV+/HPV-, EBV+/HPV+, EBV-/HPV-, with statistical significance. Nasopharyngeal cancer in the current era is closely related to EBV and HPV virus infection. Nasopharyngeal cancer patients infected with HPV alone had better treatment and survival outcomes than patients without HPV, or with EBV, or with both viruses.
Article Details
Keywords
EBV, HPV, Nasopharyngeal cancer, Nasopharyngeal carcinoma, Epstein-Barr virus, Human papiloma virus
References
2. Tang L-L, Chen W-Q, Xue W-Q, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer letters. 2016; 374(1): 22-30.
3. Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head & neck. 2014; 36(4): 511-516.
4. Verma V, Simone CB, Lin C. Human papillomavirus and nasopharyngeal cancer. Head & Neck. 2018; 40(4): 696-706.
5. Tham T, Machado R, Russo DP, Herman SW, Teegala S, Costantino P. Viral markers in nasopharyngeal carcinoma: A systematic review and meta-analysis on the detection of p16INK4a, human papillomavirus (HPV), and Ebstein-Barr virus (EBV). American Journal of Otolaryngology. 2021; 42(1): 102762.
6. Chang ET, Ye W, Zeng Y-X, Adami H-O. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiology, Biomarkers & Prevention. 2021; 30(6): 1035-1047.
7. Wu Q, Wang M, Liu Y, et al. HPV positive status is a favorable prognostic factor in non-nasopharyngeal head and neck squamous cell carcinoma patients: a retrospective study from the surveillance, epidemiology, and end results database. Frontiers in oncology. 2021; 11: 688615.
8. Verma N, Patel S, Osborn V, et al. Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma. Head & neck. 2020; 42(9): 2364-2374.
9. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world: epidemiology, incidence, mortality and risk factors. WCRJ. 2018; 5(1): e1046.
10. Huang WB, Chan JYW, Liu DL. Human papillomavirus and World Health Organization type III nasopharyngeal carcinoma: Multicenter study from an endemic area in Southern China. Cancer. 2018; 124(3): 530-536.
11. King A, Teo P, Lam W, Leung S, Metreweli C. Paranasopharyngeal space involvement in nasopharyngeal cancer: dectection by CT and MRI. Clinical Oncology. 2000; 12(6): 397-402.
12. Nguyễn Thị Liên. Xác định type HPV trên bệnh nhân ung thư vòm họng. Luận văn thạc sĩ. Trường Đại học Y Hà Nội.; 2021.